Chronic Rhinosinusitis: Diagnosis, Medical Management, and When to Consider Surgery

Abstract

Chronic rhinosinusitis (CRS) is a prevalent, heterogeneous inflammatory disorder of the paranasal sinuses and nasal mucosa, presenting significant diagnostic and therapeutic challenges. This review provides an updated, evidence-based synopsis of CRS, encompassing epidemiology, disease mechanisms, risk factors, clinical manifestations, diagnostic strategies, and contemporary management approaches, including medical and surgical interventions. Recent advances and guideline recommendations are highlighted to guide clinicians in optimizing care for patients with this complex condition.

Introduction

Chronic rhinosinusitis is defined by persistent inflammation of the nasal and paranasal sinus mucosa lasting at least 12 weeks, accompanied by characteristic symptoms and objective evidence of disease. CRS significantly impairs patients’ quality of life and imposes considerable socioeconomic burden. Its complex pathophysiology, variable presentation, and frequent recalcitrance to therapy necessitate a multidisciplinary, evidence-guided approach to diagnosis and management. This review synthesizes recent literature and consensus guidelines to provide practical, state-of-the-art guidance for clinicians.

Epidemiology / Disease Burden

CRS affects approximately 10–12% of adults worldwide. In the United States, the prevalence ranges from 5% to 16%, with substantial direct and indirect healthcare costs estimated at over $8 billion annually. CRS is a leading cause of outpatient visits, work absenteeism, and diminished productivity. The disease equally affects both sexes but may be more severe in certain populations, such as those with comorbid asthma or immunodeficiencies. The high prevalence, chronicity, and impact on health-related quality of life underscore the importance of effective diagnosis and management strategies.

Pathophysiology

CRS is a multifactorial inflammatory disease with two main phenotypes: CRS with nasal polyps (CRSwNP) and without nasal polyps (CRSsNP). The pathogenesis involves a complex interplay of host immune dysfunction, persistent mucosal inflammation, microbial biofilms, and environmental exposures. Type 2 (Th2) inflammation, characterized by elevated interleukin (IL)-4, IL-5, and IL-13, eosinophilia, and IgE production, predominates in CRSwNP, especially in Western populations. In contrast, CRSsNP is often associated with neutrophilic inflammation and a Th1/Th17 cytokine profile. Impaired mucociliary clearance, epithelial barrier dysfunction, and dysbiosis of the sinonasal microbiome further contribute to chronicity.

Risk Factors

Major risk factors for CRS include allergic rhinitis, asthma, aspirin-exacerbated respiratory disease (AERD), cystic fibrosis, immunodeficiency, primary ciliary dyskinesia, and anatomical variations such as septal deviation or concha bullosa. Environmental exposures (e.g., pollutants, tobacco smoke), frequent upper respiratory tract infections, and occupational irritants also increase susceptibility. Genetic predisposition and familial clustering are recognized, particularly in severe or refractory cases.

Clinical Features

CRS typically presents with a constellation of symptoms persisting for at least 12 weeks: nasal obstruction or congestion, mucopurulent nasal discharge (anterior/posterior), facial pain or pressure, and reduction or loss of smell. Additional features include cough, fatigue, halitosis, and ear fullness. Physical examination may reveal mucosal edema, purulent secretions, and, in CRSwNP, visible polyps. Symptom severity varies widely and frequently overlaps with other upper airway disorders, complicating diagnosis.

Diagnosis

Diagnosis of CRS requires both subjective symptoms and objective evidence of sinonasal inflammation, as per established guidelines (e.g., EPOS, AAO-HNS). Objective confirmation is achieved via nasal endoscopy (demonstrating edema, polypoid changes, or purulence) or radiographic imaging (preferably non-contrast CT), which reveals mucosal thickening, sinus opacification, or osteomeatal complex obstruction. Differential diagnosis includes acute rhinosinusitis, allergic rhinitis, migraine, and dental pathology. Biomarkers, such as tissue eosinophilia or local IgE, can be useful in selected cases. Microbiological assessment is reserved for refractory or complicated cases.

Treatment & Management

CRS management is individualized, aiming to reduce mucosal inflammation, restore sinus ventilation, and prevent recurrence. Initial therapy emphasizes medical management. Intranasal corticosteroids are the mainstay for both phenotypes; saline irrigations provide adjunctive benefit. Short courses of oral corticosteroids may be considered in severe or polypoid disease. Antibiotics are reserved for suspected bacterial exacerbations. For selected patients, leukotriene modifiers, macrolide therapy (in CRSsNP), or biologic agents (in severe CRSwNP) may be indicated. Allergen avoidance, immunotherapy, and management of comorbidities (e.g., asthma) are integral. Failure of maximal medical therapy, persistent symptoms, or complications may necessitate surgical intervention.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in CRS therapeutics, particularly for CRSwNP. Biologic agents targeting key inflammatory mediators (e.g., anti-IL-4Rα, anti-IL-5, anti-IgE) have demonstrated efficacy in reducing polyp size, improving olfaction, and decreasing the need for surgery. Endoscopic sinus surgery (ESS), increasingly guided by advanced imaging and navigation systems, offers improved outcomes in refractory cases. Research into the role of the sinonasal microbiome and personalized medicine approaches holds promise for future management.

Guideline Recommendations

Contemporary guidelines advocate a stepwise approach: confirm diagnosis with objective evidence, initiate medical therapy (intranasal corticosteroids, saline irrigation), address comorbidities, and escalate to systemic corticosteroids or targeted biologics when indicated. Surgery is recommended for patients unresponsive to optimal medical management or with anatomical obstruction. Postoperative care includes continued medical therapy to prevent recurrence. Shared decision-making and patient education are emphasized throughout care.

Conclusion

Chronic rhinosinusitis is a complex, chronic inflammatory disease necessitating a nuanced, evidence-based approach to diagnosis and management. Advances in understanding pathophysiology and the advent of targeted biologic therapies have expanded treatment options, particularly for severe and refractory cases. Adherence to guideline-driven care and multidisciplinary collaboration are essential to optimize patient outcomes and quality of life.